PerpEquities

Neraca Summit Therapeutics Inc. (SMMT)

NASDAQ · Healthcare · Biotechnology · Karyawan: 265 · CEO: Robert W. Duggan

Harga
$16,03 -1,05%
Kapitalisasi pasar
$12,8 M
Nilai perusahaan
$12,4 M
Laporan terakhir
Q2 '26 diajukan 2026-07-23
Laporan berikutnya
2026-11-02 Estimasi EPS: -$0,28

Pada akhir Q2 '26, Summit Therapeutics Inc. (SMMT) memiliki $691 jt dalam kas dan investasi jangka pendek, dengan utang $20,4 jt (termasuk sewa). Total aset $752 jt, total liabilitas $122 jt, ekuitas pemegang saham $630 jt.

Neraca

NeracaTrenQ2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q4 '25Q1 '26Q2 '26
Aset
Kas & setara kas$33,2 jt$19,6 jt$56,5 jt$48,8 jt$22,5 jt$71,5 jt$83,8 jt$164 jt$219 jt$167 jt$80,8 jt$419 jt
Investasi jangka pendek$136 jt$144 jt$90,9 jt$76 jt$235 jt$300 jt$246 jt$116 jt$0$362 jt$373 jt$271 jt
Piutang$3,64 jt$667 rb$671 rb$753 rb$753 rb$504 rb$445 rb$0$0$0$0$0
Aset lancar lainnya$1,41 jt$98,6 rb$143 rb$4,49 jt$1,87 jt$1,52 jt$8,67 jt$7,31 jt$8,34 jt$5,09 jt$13,5 jt$29,9 jt
Aset lancar$180 jt$168 jt$150 jt$130 jt$260 jt$374 jt$339 jt$287 jt$227 jt$535 jt$468 jt$721 jt
Properti, pabrik & peralatan (neto)$5,7 jt$5,45 jt$4,8 jt$7,61 jt$7,06 jt$6,29 jt$5,91 jt$5,42 jt$4,58 jt$16,1 jt$16 jt$21,2 jt
Goodwill$1,49 jt$1,49 jt$1,5 jt$1,49 jt$1,49 jt$1,52 jt$1,49 jt$1,49 jt$1,5 jt$1,49 jt$1,49 jt$1,97 jt
Aset tidak lancar lainnya$606 rb$4,17 jt$4,18 jt$1,66 jt$1,77 jt$1,78 jt$2,04 jt$3,21 jt$4,78 jt$5,35 jt$6,24 jt$8,45 jt
Aset tidak lancar$7,79 jt$11,1 jt$10,5 jt$10,8 jt$10,3 jt$9,58 jt$9,44 jt$10,1 jt$10,9 jt$22,9 jt$23,7 jt$31,6 jt
Total aset$187 jt$180 jt$161 jt$141 jt$270 jt$384 jt$348 jt$297 jt$238 jt$557 jt$491 jt$752 jt
Liabilitas
Utang usaha$779 rb$2,72 jt$2,11 jt$5,08 jt$2,64 jt$2,48 jt$3,7 jt$3,87 jt$16,9 jt$15,1 jt$20,9 jt$22,9 jt
Beban akrual$3,05 jt$3 jt$6,95 jt$5,22 jt$21,7 jt$14,1 jt$15,6 jt$16,4 jt$19,2 jt$23,8 jt$33,6 jt$9,44 jt
Utang jangka pendek$0$82,2 jt$0$0$79 jt$18,7 jt$0$0$0$0$0$3,55 jt
Liabilitas jangka pendek lainnya$3,27 jt$3,28 jt$4,86 jt$5,43 jt$4,49 jt$6,86 jt$11 jt$3,99 jt$5,93 jt$12,8 jt$6,23 jt$2,62 jt
Liabilitas jangka pendek$9,42 jt$93,5 jt$16,1 jt$18,7 jt$111 jt$45 jt$33,3 jt$27 jt$44,3 jt$54,2 jt$63,1 jt$104 jt
Utang jangka panjang$78,9 jt$0$79,1 jt$79,7 jt$0$0$0$0$0$0$0$16,8 jt
Liabilitas sewa (jangka panjang)$3,42 jt$3,19 jt$2,6 jt$4,64 jt$3,96 jt$3,21 jt$2,76 jt$2,25 jt$1,79 jt$13 jt$12,8 jt$0
Liabilitas jangka panjang lainnya$1,19 jt$1,21 jt$1,24 jt$2,64 jt$1,26 jt$1,31 jt$1,3 jt$1,32 jt$1,35 jt$1,36 jt$1,36 jt$1,8 jt
Liabilitas jangka panjang$83,6 jt$4,4 jt$83 jt$86,9 jt$5,22 jt$4,52 jt$4,06 jt$3,57 jt$3,14 jt$14,3 jt$14,1 jt$18,6 jt
Total liabilitas$93 jt$97,9 jt$99,1 jt$106 jt$116 jt$49,5 jt$37,4 jt$30,6 jt$47,4 jt$68,5 jt$77,3 jt$122 jt
Ekuitas
Saham biasa & modal disetor$5,51 jt$5,74 jt$5,55 jt$5,59 jt$5,72 jt$5,62 jt$5,89 jt$5,74 jt$5,45 jt$5,75 jt$5,88 jt$7,93 jt
Laba ditahan-$738 jt-$786 jt-$786 jt-$826 jt-$867 jt-$880 jt-$971 jt-$989 jt-$1,35 M-$1,7 M-$1,88 M-$2,7 M
Akumulasi penghasilan komprehensif lain-$1,92 jt-$1,91 jt-$1,94 jt-$1,95 jt-$1,97 jt-$1,76 jt-$1,83 jt-$1,99 jt-$2,02 jt-$1,89 jt-$2 jt-$2,67 jt
Ekuitas pemegang saham$94,4 jt$81,7 jt$61,5 jt$35,2 jt$154 jt$334 jt$311 jt$267 jt$190 jt$489 jt$414 jt$630 jt
Utang
Total utang (termasuk sewa)$84,7 jt$87,7 jt$84 jt$87,3 jt$85,9 jt$24,8 jt$5,77 jt$5 jt$4,07 jt$15,5 jt$15,2 jt$20,4 jt
Utang neto (utang - kas)$51,4 jt$68,1 jt$27,4 jt$38,4 jt$63,4 jt-$46,7 jt-$78 jt-$159 jt-$214 jt-$152 jt-$65,6 jt-$399 jt

Distandardisasi dari laporan perusahaan; arus keluar dan biaya mempertahankan tanda yang dilaporkan penyedia. Arahkan kursor ke periode untuk melihat tanggal berakhirnya. Jumlah dalam USD.

Kas, investasi, dan utang

akhir kuartal

Laporan lainnya

Sumber

Laporan keuangan, pendapatan segmen, metrik, dan estimasi distandardisasi dari laporan perusahaan. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30

Data per 2026-11-02